Hutchison MediPharma Limited (“Hutchison MediPharma”) received the 2008 International Award from the American College of Gastroenterology (“ACG”) for its presentation entitled “Herbal Extract HMPL-004 in Active Ulcerative Colitis: A Randomized Comparison with Sustained Release Mesalamine.”
Hutchison MediPharma’s presentation was made in the plenary session for inflammatory bowel disease (“IBD”) of the ACG’s 73rd annual meeting in Orlando, Florida, on 6 October 2008. In this presentation, Hutchison MediPharma released positive clinical study results of HMPL-004 for treating Ulcerative Colitis (“UC”). The study was completed in China last year, and as a result, Hutchison MediPharma is currently conducting a phase II clinical trial for Crohn’s Disease and a phase IIb trial for UC globally across US and European sites.
Dr. Samantha Du, Chief Scientific Officer of Chi-Med and CEO of Hutchison MediPharma commented: “We appreciate the honour of this award. The medical community is in great need of safer and more effective drugs for the IBD therapeutic area, and HMPL-004 shows potential in providing a good alternative to existing treatments.”
